Taysha Gene Therapies Inc (TSHA)
1.23
-0.11
(-8.21%)
USD |
NASDAQ |
Nov 05, 10:30
Taysha Gene Therapies Price to Book Value: 2.315 for Nov. 5, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 2.522 |
| November 01, 2024 | 2.880 |
| October 31, 2024 | 3.181 |
| October 30, 2024 | 3.520 |
| October 29, 2024 | 3.539 |
| October 28, 2024 | 3.708 |
| October 25, 2024 | 3.746 |
| October 24, 2024 | 3.708 |
| October 23, 2024 | 3.708 |
| October 22, 2024 | 3.746 |
| October 21, 2024 | 3.803 |
| October 18, 2024 | 3.878 |
| October 17, 2024 | 3.822 |
| October 16, 2024 | 3.822 |
| October 15, 2024 | 3.671 |
| October 14, 2024 | 3.746 |
| October 11, 2024 | 3.784 |
| October 10, 2024 | 3.727 |
| October 09, 2024 | 3.765 |
| October 08, 2024 | 3.784 |
| October 07, 2024 | 3.727 |
| October 04, 2024 | 3.784 |
| October 03, 2024 | 3.803 |
| October 02, 2024 | 3.859 |
| October 01, 2024 | 3.803 |
| Date | Value |
|---|---|
| September 30, 2024 | 3.784 |
| September 27, 2024 | 3.897 |
| September 26, 2024 | 3.953 |
| September 25, 2024 | 3.784 |
| September 24, 2024 | 3.878 |
| September 23, 2024 | 3.822 |
| September 20, 2024 | 4.047 |
| September 19, 2024 | 4.123 |
| September 18, 2024 | 4.047 |
| September 17, 2024 | 4.104 |
| September 16, 2024 | 4.085 |
| September 13, 2024 | 4.311 |
| September 12, 2024 | 4.123 |
| September 11, 2024 | 4.367 |
| September 10, 2024 | 4.311 |
| September 09, 2024 | 4.311 |
| September 06, 2024 | 3.840 |
| September 05, 2024 | 3.972 |
| September 04, 2024 | 3.897 |
| September 03, 2024 | 3.878 |
| August 30, 2024 | 4.217 |
| August 29, 2024 | 4.047 |
| August 28, 2024 | 3.934 |
| August 27, 2024 | 4.028 |
| August 26, 2024 | 4.066 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.974
Minimum
Jun 01 2022
153.19
Maximum
Jan 13 2023
10.84
Average
4.111
Median
Nov 11 2021
Price to Book Value Benchmarks
| CEL-SCI Corp | 5.893 |
| AIM ImmunoTech Inc | 2.605 |
| IGC Pharma Inc | 3.599 |
| NovaBay Pharmaceuticals Inc | -- |
| Protalix BioTherapeutics Inc | 3.319 |
Price to Book Value Related Metrics
| PS Ratio | 18.55 |
| Price | 1.23 |
| Earnings Yield | -70.30% |
| Market Cap | 252.08M |